Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jarmo, Pystynen"'
Autor:
Shouming, Wang, Anssi, Haikarainen, Antti, Pohjakallio, Julius, Sipilä, Janne, Kaskinoro, Satu, Juhila, Niina, Jalava, Mikko, Koskinen, Marja, Vesajoki, Esa, Kumpulainen, Jarmo, Pystynen, Tuula, Koskelainen, Patrik, Holm, David, Din Belle
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 77:129005
Here is reported the design and synthesis of a series of highly potent and selective α2C antagonists using benzodioxine methyl piperazine as a central scaffold by pharmacophoric analysis to improve the pharmacokinetics of suboptimal clinical candida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a79817adb5e1c73186ea6f167f3ba422
https://doi.org/10.1016/j.bmcl.2022.129005
https://doi.org/10.1016/j.bmcl.2022.129005
Autor:
Shouming, Wang, Anssi, Haikarainen, Antti, Pohjakallio, Julius, Sipilä, Janne, Kaskinoro, Satu, Juhila, Niina, Jalava, Mikko, Koskinen, Marja, Vesajoki, Esa, Kumpulainen, Jarmo, Pystynen, Tuula, Koskelainen, Patrik, Holm, David, Din Belle
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 69:128783
In this manuscript, we report a series of benzodioxine methyl piperidine derivatives as highly potent and selective α2C antagonists by ligand design to improve the pharmacokinetics of a previous candidate molecule.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d11c0582b9e57eabdf758db92785f82e
https://doi.org/10.1016/j.bmcl.2022.128783
https://doi.org/10.1016/j.bmcl.2022.128783
Autor:
Piero Pollesello, Tiainen Eija, Jarmo Pystynen, Martti Ovaska, Carola Tilgmann, Jouko Levijoki, Marjo Yliperttula, Juha Kaivola, Arto Annila
Publikováno v:
Chemical Biology & Drug Design. 81:463-473
The interplay between cardiac sarcoplasmic Ca(2+)ATPase and phospholamban is a key regulating factor of contraction and relaxation in the cardiac muscle. In heart failure, aberrations in the inhibition of sarcoplasmic Ca(2+)ATPase by phospholamban ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e30b32cc5dd4a332333c6dffaef6424e
https://doi.org/10.1111/j.1747-0285.2012.01409.x
https://doi.org/10.1111/j.1747-0285.2012.01409.x
Autor:
Carola, Tilgmann, Piero, Pollesello, Martti, Ovaska, Juha, Kaivola, Jarmo, Pystynen, Eija, Tiainen, Marjo, Yliperttula, Arto, Annila, Jouko, Levijoki
Publikováno v:
Chemical biologydrug design. 81(4)
The interplay between cardiac sarcoplasmic Ca(2+)ATPase and phospholamban is a key regulating factor of contraction and relaxation in the cardiac muscle. In heart failure, aberrations in the inhibition of sarcoplasmic Ca(2+)ATPase by phospholamban ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::372de5a6e9009f01676133c0ce7a3d85
https://pubmed.ncbi.nlm.nih.gov/22578098
https://pubmed.ncbi.nlm.nih.gov/22578098
Autor:
Marko Lehtonen, Mikko Koskinen, Jarmo Pystynen, Krista Laine, Jouko Savolainen, Jarkko Rautio, Jukka Leppänen, Mikko Sairanen
Publikováno v:
Bioorganicmedicinal chemistry letters. 20(8)
Compound 1 is an investigational, nanomolar inhibitor of catechol-O-methyltransferase (COMT) that suffers from poor oral bioavailability, most probably due to its low lipophilicity throughout most of the gastrointestinal tract and, to a lesser extent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab15ad59fba5f089e8786d889ff2ba46
https://pubmed.ncbi.nlm.nih.gov/20231095
https://pubmed.ncbi.nlm.nih.gov/20231095